Alexander KarpAlexander Karp earned $1B in 2024

In 2024, Daniel O'Day earned $21.90M in total compensation at Gilead Sciences, including $1.77M salary and $18.79M in stock. Most recently acquired 224,504 shares in Feb 2025. Currently holds stock worth $69.93M. 6+ years at the helm of Gilead Sciences.

Compensation History

Annual executive compensation data for Daniel O'Day, including salary, bonuses, and stock awards.

Year

2024

Total Compensation

$21.90M

Salary

$1.77M

Bonus

$0.00

Other

$1.34M

Salary

$1.77M

Board Justification

Our executive compensation program is designed through thoughtful application of a combination of pay elements to promote an adept, driven executive team whose incentives align with Gilead’s and stockholder interests.

Bonus

$0.00

Board Justification

N/A

Other Compensation

$1.34M

Board Justification

Includes the 2024 value of perquisites and other personal benefits, company contributions to our Section 401(k) plan, and term life insurance premiums. $1,311,784, which includes (i) a final $750,000 of company contribution credited to Mr. O’Day’s deferred compensation plan account on March 1, 2024. These contributions were provided to compensate him for the forfeiture of his pension benefits with his former employer; (ii) $35,517 reflecting the aggregate incremental cost incurred by us for Mr. O’Day’s personal use of our corporate automobiles; (iii) $240,998 reflecting the aggregate incremental cost incurred by us for the personal use of our corporate aircraft; and (iv) $285,269 reflecting the aggregate incremental cost incurred by us for security services provided to Mr. O’Day.

Restricted Stock

$18.79M240.7K Common Stock

Board Justification

Shares acquired upon vesting of RSUs and/or performance shares

Performance Metrics

Net Product Revenue, Relative TSR, Non-GAAP Operating Income

G

Daniel O'Day

CEO of Gilead Sciences

Education

B.S. degree in biology from Georgetown University, M.B.A. from Columbia Business School

Field of Expertise

Healthcare & Life Sciences - Pharmaceuticals

Sector of Economy

Healthcare

Born

November 30, 1964 - 61 years ago

CEO of Gilead Sciences for

6 years 9 months (Mar 2019 - Present)

Previous Experience

CEO of Roche Pharmaceuticals

Holdings

Track Daniel O'Day's stock holdings and portfolio value over time.

Insider Trading

Daniel O'Day's recent stock transactions, purchases, and sales filed with the SEC.

GILD

224,504 shares

GILD

Feb 4, 2025

Received

GILD

230,747 shares

GILD

Jan 31, 2024

Received

GILD

215,017 shares

GILD

Jan 24, 2023

Received

GILD

146,678 shares

GILD

Jan 26, 2022

Received

GILD

59,100 shares

GILD

Jan 26, 2021

Received

GILD

19,204 shares

GILD

Jan 29, 2020

Received

Rivals

Compare Daniel O'Day with competitor CEOs and industry peers.